Director Anne Phillips receives 39,567 Sagimet (SGMT) stock options at $6.48 strike

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Sagimet Biosciences Inc. director Anne M. Phillips received a grant of stock options covering 39,567 shares of Series A Common Stock at an exercise price of $6.48 per share. These options were awarded as compensation and are held directly.

The options vest and become exercisable in twelve equal monthly installments following June 12, 2026, contingent on her continued service on each vesting date. Following this grant, she holds stock options for 39,567 underlying shares, all from this award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Phillips Anne M.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	39,567	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 39,567 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 39,567 shares Exercise price: $6.48 per share Underlying shares: 39,567 shares +3 more

6 metrics

Options granted 39,567 shares Stock Option (Right to Buy) granted to director

Exercise price $6.48 per share Conversion or exercise price of stock option

Underlying shares 39,567 shares Series A Common Stock covered by option

Total derivatives after grant 39,567 options Total shares following transaction

Option expiration June 11, 2036 Expiration date of the granted option

Vesting schedule 12 monthly installments Equal monthly vesting after June 12, 2026

Key Terms

Stock Option (Right to Buy), Series A Common Stock, exercise price, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Series A Common Stock financial

"underlying_security_title: Series A Common Stock"

Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.

exercise price financial

"conversion_or_exercise_price: 6.4800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/15/2026 - 04:20 PM Accepted by SEC EDGAR 06/15/2026 - 04:19 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Phillips Anne M.

(Last)

(First)

(Middle)

SAGIMET BIOSCIENCES INC.

155 BOVET ROAD, SUITE 303

(Street)

SAN MATEO

CALIFORNIA

94402

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sagimet Biosciences Inc. [ SGMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$6.48	06/12/2026		A		39,567		⁽¹⁾	06/11/2036	Series A Common Stock	39,567	$0	39,567	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Elizabeth Rozek, Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Sagimet Biosciences (SGMT) report for Anne M. Phillips?

Sagimet Biosciences reported that director Anne M. Phillips received a grant of stock options for 39,567 shares of Series A Common Stock at a $6.48 exercise price. This is a compensation-related award, not an open-market share purchase or sale.

How many Sagimet Biosciences (SGMT) shares are covered by Anne M. Phillips’ new options?

The new stock option grant to Anne M. Phillips covers 39,567 underlying shares of Sagimet Biosciences Series A Common Stock. These options were granted at a $6.48 exercise price and represent her entire reported derivative position after the transaction.

What is the exercise price and expiration date of Anne M. Phillips’ Sagimet (SGMT) options?

The granted stock options have a $6.48 per share exercise price and expire on June 11, 2036. This long-dated award gives the director the right to buy shares at that price if the options vest and are later exercised.

How do Anne M. Phillips’ Sagimet (SGMT) stock options vest?

The options vest in twelve equal monthly installments after June 12, 2026, subject to Anne M. Phillips’ continued service. Each month a portion becomes exercisable, aligning the award with ongoing board service over the one-year vesting period.

Is Anne M. Phillips buying or selling Sagimet Biosciences (SGMT) stock in this Form 4?

This Form 4 shows an acquisition of stock options as a grant, not an open-market buy or sale of shares. The transaction is coded as an award, reflecting equity-based compensation rather than a discretionary stock trade.